课题基金 / 基金详情

Biodegradable hollow CuS nanoparticles for photothermal cancer therapy

Biodegradable hollow CuS nanoparticles for photothermal cancer therapy
用于光热癌症治疗的可生物降解空心 CuS 纳米粒子
批准号:
8739288
负责人:
Wei Lu
金额:
$32.92万
依托单位:
依托单位国家:
美国
项目类别:
财政年份:
2013
资助国家:
美国
项目状态:
已结题
起止时间:
2013-09-30 至 2017-08-31

项目摘要

项目成果

Wei Lu的其他基金

相似基金

相关文献

中文摘要
翻译
描述(由申请人提供):光热消融(PTA)疗法为无法手术的肿瘤提供了一种微创治疗。金纳米结构等纳米粒子具有较强的光热耦合效应,可显著提高PTA的效能。另一方面,目前使用的PTA有一些局限性,如治疗转移性癌症的效果较差;纳米颗粒的不可生物降解性,以及纳米颗粒在灌注不良的肿瘤部位进入肿瘤间质的限制性运输。这个
英文摘要
DESCRIPTION (provided by applicant): Photothermal ablation (PTA) therapy provides a minimally invasive treatment for inoperable tumors. Nanoparticles such as gold nanostructures, along with strong photothermal coupling effect, have been shown to greatly enhance the efficacy of PTA. On the other hand, currently used PTA has several limitations such as less effectiveness in treating metastatic cancer; non-biodegradability of the nanoparticles, and restrictive transport of nanoparticles into tumor interstitium in a poorly perfused tumor site. The restrictive transport likely results in sublethal dose of heat transfer and may cause tumor recurrence and develop resistance. Hollow CuS nanoparticles (HCuSNPs) belong to a new class of photothermal nanoparticles. As shown in our Preliminary Study, HCuSNPs, in contrast to gold analogs, were biodegradable and eliminated through the kidney. We hypothesize that the HCuSNPs provide advanced multimodality photothermal therapeutic approaches for control of tumor recurrence and metastases. The Specific Aims of this project are: (1) to evaluate metabolism and toxicity of HCuSNPs; (2) to develop HCuSNPs-mediated multistage delivery for cancer photothermal therapy; and (3) to explore HCuSNPs-adjuvant-mediated in situ photoimmunotherapy (ISPI). In Aim 1, we will examine the cellular fate and metabolism of the PEG-HCuSNPs; and analyze single and repeated dose toxicity of the PEG-HCuSNPs. In Aim 2, we will use photoacoustic imaging to analyze the stages of tumor delivery of HCuSNPs in mouse tumor xenograft model; and validate the effect of PTA through the multistage delivery. In Aim 3, we will assess the immune response induced by HCuSNPs-adjuvant-mediated ISPI; and evaluate the local and distal anti-tumor effect. These studies will be performed in xenograft, allograft and spontaneous models of breast cancer. Worldwide, breast cancer is the second most frequently diagnosed malignancy in women. A success in validating the proposed multimodality PTA will provide an important therapeutic strategy not only for primary but also for metastatic breast cancer. Clearly, this technology, in combination with the use of fiberoptics, can be used to treat a broad range of cancers even in deep tissues.
期刊论文(0)
专著(0)
科研奖励(0)
会议论文
Structural and functional studies of the human TRPM4 and TRPM5 channels
  • 批准号:
    10421062
  • 项目类别:
  • 资助金额:
    $57.98万
  • 财政年份:
    2020
  • 负责人:
    Wei Lu
  • 依托单位:
Elucidating structures and molecular mechanisms of Pannexin channels
  • 批准号:
    10028649
  • 项目类别:
  • 资助金额:
    $47.5万
  • 财政年份:
    2020
  • 负责人:
    Wei Lu
  • 依托单位:
Structural and functional studies of the human TRPM4 and TRPM5 channels
  • 批准号:
    10591577
  • 项目类别:
  • 资助金额:
    $57.98万
  • 财政年份:
    2020
  • 负责人:
    Wei Lu
  • 依托单位:
Structural and functional studies of CALHM channels
  • 批准号:
    10573257
  • 项目类别:
  • 资助金额:
    $47.33万
  • 财政年份:
    2020
  • 负责人:
    Wei Lu
  • 依托单位:
海外基金